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Regarding “Heparin-bonded Dacron or
polytetrafluoroethylene for femoro-popliteal bypass
grafting: A multicenter trial”
We have read with interest the article by Devine and
McCollum (J Vasc Surg 2001;33:533-9) on femoropopliteal arte-
rial reconstructions comparing heparin-bonded Dacron grafts
versus non–heparin-treated PTFE control grafts. The title of this
important study suggests that the improved outcome demon-
strated for the heparin-bonded Dacron grafts is related somehow
to the antithrombotic properties of the bonded heparin that is
exposed on the inner graft surface to the circulating blood stream.
This assumption is well in line with previous work demonstrating
improved thrombo-resistance for heparin surface coated devices
exposed to the blood stream under various conditions.1-3
Unfortunately, clot production has been demonstrated clini-
cally for patients perfused with heparin-coated devices, after infu-
sion of protamine during the perfusion period.4 It was also
demonstrated for the experimental set-up that heparin-coated
devices exposed to circulating protamine produced more clots
than both uncoated controls perfused sequentially under the
same conditions and heparin surface coated devices perfused
without systemic heparinization.5 Hence, it has to be accepted
that circulating protamine neutralizes the antithrombotic proper-
ties of heparin surface treatments.
Devine and McCollum have not reported the detailed
periprocedural anticoagulation regimens used for the study group
receiving heparin-bonded grafts and the control patients included
in their report (only aspirin 300 mg/d is mentioned). However,
if some systemic heparin was given before cross-clamping, and
eventually protamine was used at the end of the procedure, it can
be expected, based on the experiences mentioned above, that the
heparin on the inner graft surface, which was exposed to circulat-
ing protamine, was neutralized, and therefore the antithrombotic
properties of the inner graft surface were lost. Hence, under such
circumstances it seems to be unrealistic to attribute the superior
patency rates of the study group to bonded heparin.
On the other hand, if the authors have avoided protamine in
the patients of the study group, this should be clearly stated, and
a caveat mentioning the downsides of protamine application in
the presence of heparin-bonded synthetic grafts seems to be
appropriate for the readers of the Journal.
Ludwig K. von Segesser, MD, FACS, FETCS
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Reply
Dr Von Segesser and colleagues read more into our title than
was intended. This was a clinical trial comparing two types of
grafts. Our discussion points out that we have no convincing evi-
dence to attribute the improved results with heparin-bonded
Dacron to the heparin bonding. Rather, we suggest that the
results with PTFE are poor, particularly with respect to subsequent
amputation.
It is normal practice in the UK to give heparin systemically
prior to applying cross clamps. However, some surgeons give
regional heparin only and heparin saline was infused into the dis-
tal tree after making the arteriotomy in 16 of the 209 recon-
structions. It is not normal practice in the UK to give protamine
and none of our patients received protamine.
We agree that it would be illogical to give protamine to any
patient in whom a heparin bonded device was being implanted.
We know that protamine reversal of heparin may be disastrous in
carotid surgery (Fearn SJ, Parry AD, Picton AJ, Mortimer AJ,
McCollum CN. Eur J Vasc Endovasc Surg 1997;13:394-7), but I
suspect there is little evidence of an effect on distal arterial recon-
struction.
Carol Devine, BA (hons)
Charles McCollum, MD, FRCS
University Hospital of South Manchester
Manchester, United Kingdom
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Regarding “The 50th anniversary of abdominal
aortic reconstruction”
Landmark events in medicine are usually grounded in the
thought and research of many people. Without taking credit from
Dubost, Oudot, and their colleagues for their audacity and inge-
nuity in performing the first aneurysm repair, one should also give
credit to the mentor who likely guided them. Given the state of
surgical technology and anesthesia in 1950, it took incredible
courage to apply what was only a minimal laboratory experience
with aortic homografts to a new clinical application. Was there
someone who provided inspiration to perform that surgery?
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